Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Current Assets (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Current Assets for 7 consecutive years, with $60.6 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 47.68% to $60.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.6 million through Dec 2025, up 47.68% year-over-year, with the annual reading at $60.6 million for FY2025, 47.68% up from the prior year.
  • Current Assets hit $60.6 million in Q4 2025 for Eton Pharmaceuticals, down from $72.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $72.0 million in Q3 2025 to a low of $16.4 million in Q3 2022.
  • Historically, Current Assets has averaged $32.7 million across 5 years, with a median of $26.6 million in 2023.
  • Biggest five-year swings in Current Assets: plummeted 38.06% in 2022 and later surged 169.1% in 2025.
  • Year by year, Current Assets stood at $23.6 million in 2021, then dropped by 15.25% to $20.0 million in 2022, then soared by 34.17% to $26.8 million in 2023, then soared by 52.84% to $41.0 million in 2024, then surged by 47.68% to $60.6 million in 2025.
  • Business Quant data shows Current Assets for ETON at $60.6 million in Q4 2025, $72.0 million in Q3 2025, and $68.4 million in Q2 2025.